Effect of MMF institution on immunological and clinical disease parameters in patients with SLE after a significant rise of antibodies to dsDNA (n=10). Data are expressed as mean (SE)
| Start | End of 6 month treatment period | p Value | |
|---|---|---|---|
| VAS-Pa and VAS-Ph denote the visual analogue score of the patient and treating physician, respectively, for lupus disease activity in the previous month, both on a scale from 0 to 100. | |||
| VAS-Pa | 42.9 (7.7) | 20.4 (5.6) | <0.001 |
| VAS-Ph | 10.3 (1.6) | 8.4 (2.0) | NS |
| Anti-dsDNA (IU/ml) | 132.3 (25.8) | 51.1 (13.1) | <0.001 |
| IgG (g/l) | 23.1 (3.0) | 19.5 (2.1) | NS |
| C3 (g/l) | 0.97 (0.08) | 1.03 (0.08) | NS |
| C4 (g/l) | 0.13 (0.01) | 0.16 (0.01) | NS |
| SLEDAI | 4.4 (0.5) | 3.4 (0.6) | NS |
| WBC (×109/l) | 5.9 (0.64) | 5.9 (0.55) | NS |
| Lymphocytes (×109/l) | 1.1 (0.17) | 1.1 (0.18) | NS |
| % CD19+CD38++ | 15.7 (1.7) | 7.7 (0.9) | <0.001 |
| % CD4+CD25+ | 35.8 (3.7) | 40.1 (3.8) | NS |
| % CD8+HLA-DR+ | 18.8 (3.9) | 24.1 (5.7) | NS |
| Haemoglobin (mmol/l) | 7.6 (0.25) | 7.4 (0.26) | NS |
| Thrombocytes (×109/l) | 302 (29) | 318 (35 | NS |